abstract |
The present invention relates to immunoglobulins, and in particular to antibodies that specifically bind to human interleukin 13 (hIL-13). The antibodies of the present invention may be used to treat a variety of diseases or disorders that are responsive to modulation of the interaction between hIL-13 and the human IL-13 receptor. Such diseases include severe asthma, atopic dermatitis, COPD and various fibrotic diseases. Also disclosed are pharmaceutical compositions and methods of manufacture comprising the antibodies. |